Drugs / tumor necrosis factor

Trials 6 · a red edge is where a trial was stopped

19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT00436410 Dec 2006 → Aug 2009 adrenal cortex carcinoma, breast cancer, colorectal cancer, cutaneous melanoma +4 National Institutes of Health Clinical Center (CC) Completed No outcome recorded
Phase 11 trial
Phase 1 NCT00002262 HIV infectious disease, Kaposi's sarcoma University of California, San Francisco Completed No outcome recorded
Phase 22 trials
Phase 2 NCT00019968 Aug 1999 → Mar 2002 soft tissue sarcoma National Institutes of Health Clinical Center (CC) Completed No outcome recorded
Phase 2 NCT00001004 ? → Feb 1990 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 32 trials
Phase 3 NCT00003789 Mar 1999 → Jan 2004 melanoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 3 NCT00001296 Feb 1992 → Oct 2000 melanoma National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as tumor necrosis factor ClinicalTrials.gov intervention name — accepted as the source's own label NCT00436410
5

NCT00001004

NCT00001296

NCT00002262

NCT00019968

NCT00003789

Known as NSC-635257 “Tumor Necrosis Factor (Knoll), TNF, NSC-635257; Interferon gamma (Genentech), IFN-G, NSC-600662.” NCT00001296
Known as Recombinant Tumor Necrosis Factor Recombinant Tumor Necrosis Factor and Recombinant Human Interferon-gamma in Patients With AIDS Related Complex” NCT00001004
Known as TNF “To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated...” NCT00002262
2

“Arm I: Patients receive isolated limb perfusion (ILP) with tumor necrosis factor (TNF) and melphalan.” NCT00019968

“Tumor Necrosis Factor (Knoll), TNF, NSC-635257; Interferon gamma (Genentech), IFN-G, NSC-600662.” NCT00001296

Action Inhibit “TNF and IFN-G, in combination, can not only inhibit HIV infection of previously uninfected cells” NCT00001004
Modality Protein / enzyme biologic “Recombinant TNF” NCT00001004
Route Intramuscular “TNF alone by intramuscular injection (IM)” NCT00001004